TEVA PHARMACEUTICAL INDUSTRIES LIMITED Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 2.54M shares, a 97.90% increase from fiscal 2024.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.28M shares.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 2.54M shares 10-K · filed 2026-02-03 | |
| 2024-12-31 | 1.28M shares 10-K · filed 2026-02-03 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2026-02-03 | |
| 2022-12-31 | 0.00 shares 10-K · filed 2025-02-05 | |
| 2019-12-31 | 11.00K shares 10-K · filed 2022-02-09 | |
| 2018-12-31 | 84.00K shares 10-K · filed 2021-02-10 | |
| 2017-12-31 | 7.00K shares 10-K · filed 2020-02-21 | |
| 2016-12-31 | 766.00K shares 10-K · filed 2019-02-19 |